A review on schizophrenia and relapse - A quest for user-friendly psychopharmacotherapy

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: Schizophrenia in general is notoriously associated with relapses rendering the illness progressive to worse outcomes, a concept of which is compatible with neurotoxicity. Therefore, relapse prevention is of utmost clinical relevance. Methods: In this review, we aim to put relapse into clinical context in the realm of natural history of, or heterogeneity in, schizophrenia and summarize risk factors of relapse. We discuss how to effectively 'define' relapse in schizophrenia and recent meta-analytic studies on this topic to highlight the importance of continuous antipsychotic treatment. Results: The following issues emerged: 'How low maintenance antipsychotic dosage could be?', 'How extended dosing could be?', 'Who could be successfully withdrawn from antipsychotics?' and 'How relapse could be defined in the first place?' The question in particular is how better to deliver antipsychotics at the lowest possible, whereby dose and dosing interval are relevant. While ongoing antipsychotic treatment is the rule, recent works are pointing to a possibility of lower dosage in the maintenance phase of the illness. Conclusions: Bearing in mind that suboptimal adherence and withdrawal from antipsychotics are an established and unequivocal risk factor for relapse, further investigations are certainly needed to explore user-friendly manner of psychopharmacotherapy to prevent relapse in schizophrenia.

Original languageEnglish
Pages (from-to)414-426
Number of pages13
JournalHuman Psychopharmacology
Volume29
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Schizophrenia
Antipsychotic Agents
Recurrence
Maintenance
Secondary Prevention
Natural History
Therapeutics

Keywords

  • Antipsychotics
  • Prevention
  • Relapse
  • Review
  • Schizophrenia

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Pharmacology (medical)

Cite this

A review on schizophrenia and relapse - A quest for user-friendly psychopharmacotherapy. / Suzuki, Takefumi; Uchida, Hiroyuki; Takeuchi, Hiroyoshi; Tsuboi, Takashi; Hirano, Jinichi; Mimura, Masaru.

In: Human Psychopharmacology, Vol. 29, No. 5, 2014, p. 414-426.

Research output: Contribution to journalArticle

@article{cc9596d096ea4aa3b0e6461fdafdf1c1,
title = "A review on schizophrenia and relapse - A quest for user-friendly psychopharmacotherapy",
abstract = "Objective: Schizophrenia in general is notoriously associated with relapses rendering the illness progressive to worse outcomes, a concept of which is compatible with neurotoxicity. Therefore, relapse prevention is of utmost clinical relevance. Methods: In this review, we aim to put relapse into clinical context in the realm of natural history of, or heterogeneity in, schizophrenia and summarize risk factors of relapse. We discuss how to effectively 'define' relapse in schizophrenia and recent meta-analytic studies on this topic to highlight the importance of continuous antipsychotic treatment. Results: The following issues emerged: 'How low maintenance antipsychotic dosage could be?', 'How extended dosing could be?', 'Who could be successfully withdrawn from antipsychotics?' and 'How relapse could be defined in the first place?' The question in particular is how better to deliver antipsychotics at the lowest possible, whereby dose and dosing interval are relevant. While ongoing antipsychotic treatment is the rule, recent works are pointing to a possibility of lower dosage in the maintenance phase of the illness. Conclusions: Bearing in mind that suboptimal adherence and withdrawal from antipsychotics are an established and unequivocal risk factor for relapse, further investigations are certainly needed to explore user-friendly manner of psychopharmacotherapy to prevent relapse in schizophrenia.",
keywords = "Antipsychotics, Prevention, Relapse, Review, Schizophrenia",
author = "Takefumi Suzuki and Hiroyuki Uchida and Hiroyoshi Takeuchi and Takashi Tsuboi and Jinichi Hirano and Masaru Mimura",
year = "2014",
doi = "10.1002/hup.2421",
language = "English",
volume = "29",
pages = "414--426",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - A review on schizophrenia and relapse - A quest for user-friendly psychopharmacotherapy

AU - Suzuki, Takefumi

AU - Uchida, Hiroyuki

AU - Takeuchi, Hiroyoshi

AU - Tsuboi, Takashi

AU - Hirano, Jinichi

AU - Mimura, Masaru

PY - 2014

Y1 - 2014

N2 - Objective: Schizophrenia in general is notoriously associated with relapses rendering the illness progressive to worse outcomes, a concept of which is compatible with neurotoxicity. Therefore, relapse prevention is of utmost clinical relevance. Methods: In this review, we aim to put relapse into clinical context in the realm of natural history of, or heterogeneity in, schizophrenia and summarize risk factors of relapse. We discuss how to effectively 'define' relapse in schizophrenia and recent meta-analytic studies on this topic to highlight the importance of continuous antipsychotic treatment. Results: The following issues emerged: 'How low maintenance antipsychotic dosage could be?', 'How extended dosing could be?', 'Who could be successfully withdrawn from antipsychotics?' and 'How relapse could be defined in the first place?' The question in particular is how better to deliver antipsychotics at the lowest possible, whereby dose and dosing interval are relevant. While ongoing antipsychotic treatment is the rule, recent works are pointing to a possibility of lower dosage in the maintenance phase of the illness. Conclusions: Bearing in mind that suboptimal adherence and withdrawal from antipsychotics are an established and unequivocal risk factor for relapse, further investigations are certainly needed to explore user-friendly manner of psychopharmacotherapy to prevent relapse in schizophrenia.

AB - Objective: Schizophrenia in general is notoriously associated with relapses rendering the illness progressive to worse outcomes, a concept of which is compatible with neurotoxicity. Therefore, relapse prevention is of utmost clinical relevance. Methods: In this review, we aim to put relapse into clinical context in the realm of natural history of, or heterogeneity in, schizophrenia and summarize risk factors of relapse. We discuss how to effectively 'define' relapse in schizophrenia and recent meta-analytic studies on this topic to highlight the importance of continuous antipsychotic treatment. Results: The following issues emerged: 'How low maintenance antipsychotic dosage could be?', 'How extended dosing could be?', 'Who could be successfully withdrawn from antipsychotics?' and 'How relapse could be defined in the first place?' The question in particular is how better to deliver antipsychotics at the lowest possible, whereby dose and dosing interval are relevant. While ongoing antipsychotic treatment is the rule, recent works are pointing to a possibility of lower dosage in the maintenance phase of the illness. Conclusions: Bearing in mind that suboptimal adherence and withdrawal from antipsychotics are an established and unequivocal risk factor for relapse, further investigations are certainly needed to explore user-friendly manner of psychopharmacotherapy to prevent relapse in schizophrenia.

KW - Antipsychotics

KW - Prevention

KW - Relapse

KW - Review

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84922663829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922663829&partnerID=8YFLogxK

U2 - 10.1002/hup.2421

DO - 10.1002/hup.2421

M3 - Article

VL - 29

SP - 414

EP - 426

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 5

ER -